Physician profile
Mark Steven Grenitz
NPI 1790746279
$1,894.68
in general payments reported to CMS, 2019-2025
14 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.06 · 2020: $932 · 2021: $31.98 · 2022: $18.86 · 2023: $349 · 2024: $179 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.18 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $901.68 | 2020 | |
| Astellas Pharma US INC | $326.47 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $217.32 | 2023-2025 | Aptima, Affirm Prone Biopsy System |
| Mayne Pharma Commercial LLC | $105.42 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.51 | 2021-2025 | |
| Abbvie INC. | $87.28 | 2023-2024 | |
| Avion Pharmaceuticals | $25.78 | 2019-2020 | |
| Evofem Biosciences, INC. | $25.00 | 2024 | |
| Coopersurgical, INC. | $21.49 | 2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $19.66 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $18.05 | 2020 | |
| Exeltis, USA INC. | $15.38 | 2023 | Slynd |
| Amag Pharmaceuticals, INC. | $15.16 | 2019 | |
| Myovant Sciences INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Grenitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.